# 510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY

A. 510(k) Number: k060375   
B. Purpose for Submission: New Device   
C. Measurand: T, B, and natural killer (NK) cells as well as the CD4 and CD8 subpopulations of T cells   
D. Type of Test: Quantitative and Semi-quantitative flow cytometric assay   
A. Applicant: BD BIOSCIENCES   
F. Proprietary and Established Names: BD Multitest 6-Color TBNK Reagent with BD Trucount Tubes   
G. Regulatory Information:

<table><tr><td rowspan=1 colspan=1>Product Code</td><td rowspan=1 colspan=1>Classification</td><td rowspan=1 colspan=1>Regulation Section</td><td rowspan=1 colspan=1>Panel</td></tr><tr><td rowspan=1 colspan=1>GKZ</td><td rowspan=1 colspan=1>Class II</td><td rowspan=1 colspan=1>864.5220Automated Differential CellCounter</td><td rowspan=1 colspan=1>Hematology(81)</td></tr></table>

# H. Intended Use:

1. Intended use(s):

BD Multitest 6-Color TBNK reagent with BD Trucount tubes is intended for in vitro diagnostic use with the BD FACSCanto system to identify and determine the percentages and absolute counts of T, B, and natural killer (NK) cells as well as the CD4 and CD8 subpopulations of T cells in peripheral blood.

2. Indication(s) for use:

For use with the BD FACSCanto flow cytometer.

For use with whole blood collected in K3 EDTA tubes.

For use in the identification and determination of percentages and absolute counts of T, B, and natural killer (NK) cells as well as the CD4 and CD8 subpopulations of T cells in peripheral blood.

For in vitro diagnostic use.

3. Special conditions for use statement(s): Not Applicable

4. Special instrument requirements: BD Multitest 6-Color TBNK reagent is for use with the BD FACSCanto system.

# I. Device Description:

BD Multitest 6-color TBNK reagent with BD Trucount tubes is packaged in a kit consisting of one vial containing sufficient reagent to yield 50 tests, and two pouches, each containing 25 BD Trucount tubes. One BD Trucount tube is required for each test, and each tube is for single-use only.

The BD Multitest 6-color TBNK reagent is provided in $1 \mathrm { m L }$ of buffered saline with $0 . 1 \%$ sodium azide. The following antibodies comprise the reagent:

<table><tr><td rowspan=1 colspan=1>Antibody</td><td rowspan=1 colspan=1>Clone</td><td rowspan=1 colspan=1>Fluorochrome</td></tr><tr><td rowspan=1 colspan=1>CD4</td><td rowspan=1 colspan=1>SK3</td><td rowspan=1 colspan=1>Phycoerythrin-Cyanine 7 (PE-Cy7)</td></tr><tr><td rowspan=1 colspan=1>CD8</td><td rowspan=1 colspan=1>SK1</td><td rowspan=1 colspan=1>Allophycocyanin-Cyanine 7 (APC-Cy7)</td></tr><tr><td rowspan=1 colspan=1>CD3</td><td rowspan=1 colspan=1>SK7</td><td rowspan=1 colspan=1>Fluorescein Isothiocynate (FITC)</td></tr><tr><td rowspan=1 colspan=1>CD19</td><td rowspan=1 colspan=1>SJ25C1</td><td rowspan=1 colspan=1>Allophycocyanin (APC)</td></tr><tr><td rowspan=1 colspan=1>CD16+CD56</td><td rowspan=1 colspan=1>B73.1 / NCAM16.2</td><td rowspan=1 colspan=1>Phycoerythrin (PE)</td></tr><tr><td rowspan=1 colspan=1>CD45</td><td rowspan=1 colspan=1>2D1 (HLe-1)</td><td rowspan=1 colspan=1>Peridinin chlorophyll protein  Cyanine 5.5 (PerCP-Cy5.5)</td></tr></table>

BD Trucount tubes each contain a freeze-dried pellet of fluorescent beads held by a metal retainer at the bottom of the tube.

J. Substantial Equivalence Information:   

<table><tr><td colspan="1" rowspan="1">Predicate</td><td colspan="1" rowspan="1">Item</td><td colspan="1" rowspan="1">Similarities</td><td colspan="1" rowspan="1">Differences</td></tr><tr><td colspan="1" rowspan="1">K980858 - BDMultitest IMKKit with BDTrucountTubes</td><td colspan="1" rowspan="1">IntendedUse</td><td colspan="1" rowspan="1">Identification and determinationof percentages and absolutecounts of the following maturehuman lymphocyte subsets inerythrocyte-lysed whole blood: Tlymphocytes (CD3+, CD3+CD4+,and CD3+CD8+), B lymphocytes(CD3-CD19+), and NKlymphocytes (CD3-CD16+CD56+)</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">K980858 - BDMultitest IMKKit with BDTrucountTubes</td><td colspan="1" rowspan="1">ComponentsincludingCluster Designation, Conjugation,a Clone)</td><td colspan="1" rowspan="1">BD MultitestCD3/CD16+CD56/CD45/CD19 (1vial, 50 tests) including CD3FITC (SK7), CD16 PE (B73.1) +CD56 PE (NCAM16.2), CD45PerCP (2D1), CD19 APC(SJ25C1), and buffer with 0.1%sodium azideBD MultitestCD3/CD8/CD45/CD4 (1 vial, 50tests) including CD3 FITC (SK7),CD8 PE (SK1), CD45 PerCP(2D1), CD4 APC (SK3), andbuffer with 0.1% sodium azideBD FACS Lysing SolutionBD Trucount Tubes (100 tubes)</td><td colspan="1" rowspan="1">BD Multitest 6-Color TBNKReagent (1 vial, 50 tests)including CD4 PE-Cy7 (SK3),CD8 APC-Cy7 (SK1), CD3FITC (SK7), CD19 APC(SJ25C1), CD16 PE (B73.1) +CD56 PE (NCAM16.2), CD45PerCP-Cy5.5 (2D1), and bufferwith 0.1% sodium azideBD FACS Lysing Solution (notincluded with the reagent)BD Trucount Tubes (50 tubes)</td></tr><tr><td colspan="1" rowspan="1">K980858 - BDMultitest IMKKit with BDTrucountTues</td><td colspan="1" rowspan="1">Specificity</td><td colspan="1" rowspan="1">Specificities of antibodies havebeen verified by the InternationalWorkshop on Human LeukocyteDifferentiation Antigens.</td><td colspan="1" rowspan="1">Same.</td></tr><tr><td colspan="1" rowspan="1">K980858 - BDMultitest IMKKit with BDTrucountTubes</td><td colspan="1" rowspan="1">Method toIdentifyPopulationsof Interest</td><td colspan="1" rowspan="1">Lyse/no-wash method using atwo-tube panel with four-colorantibody reagents (one tubestained withCD3/CD16+CD56/CD45/CD19,the other withCD3/CD8/CD45/CD4) to identifylymphocytes with specific cell-surface antigens, fluorescencetriggering, and CD45 vs. SSC forgating. Uses fluorescent beads toquantify absolute counts</td><td colspan="1" rowspan="1">Same, except uses a one-tubepanel with six-color antibodyreagent</td></tr><tr><td colspan="1" rowspan="1">K980858 - BDMultitest IMKKit with BDTrucountTubes</td><td colspan="1" rowspan="1">Control</td><td colspan="1" rowspan="1">Recommend use of commerciallyavailable whole blood controlwith established values for subsetpercentages and absolute counts</td><td colspan="1" rowspan="1">Recommend use of two levels ofcommercially available wholeblood controls with establishedvalues for subset percentagesand absolute counts. BDspecifically recommends theuse of BD Multi-Check and BDMulti-Check CD4 Low controls</td></tr><tr><td colspan="1" rowspan="1">K041074 - BDFACSCantoSystem withBDFACSCantoClinicalSoftware</td><td colspan="1" rowspan="1">InstrumentandSoftware</td><td colspan="1" rowspan="1">BD FACSCanto flow cytometerwith BD FACSCanto clinicalsoftware version 1.0</td><td colspan="1" rowspan="1">Same, except uses version 2.0 ofBD FACSCanto clinicalsoftware</td></tr><tr><td colspan="1" rowspan="1">K041074 - BDFACSCantoSystem withBDFACSCantoClinicalSoftware</td><td colspan="1" rowspan="1">SystemSetup</td><td colspan="1" rowspan="1">BD FACSCanto flow cytometerwith BD FACSCanto clinicalsoftware version 1.0 and BDFACS 7-color setup beads</td><td colspan="1" rowspan="1">Same, except uses version 2.0 ofBD FACSCanto clinicalsoftware</td></tr><tr><td colspan="1" rowspan="1">K980858 - BDMultitest IMKKit with BDTrucountTubes</td><td colspan="1" rowspan="1">Sampleand StainStability</td><td colspan="1" rowspan="1">Anticoagulated blood stored atroom temperature (2025°C)must be stained within 48 hoursof draw and then analyzed within24 hours of staining</td><td colspan="1" rowspan="1">Anticoagulated blood stored atroom temperature (2025°C)must be stained within 24 hoursof draw and then analyzedwithin 6 hours of staining</td></tr><tr><td colspan="1" rowspan="1">K980858 - BDMultitest IMKKit with BDTrucountTubes</td><td colspan="1" rowspan="1">Results</td><td colspan="1" rowspan="1">CD3+, CD3+CD4+, andCD3+CD8+ T lymphocytes; CD3-CD19+ B lymphocytes, and CD3-CD16+CD56+ NK lymphocytesexpressed as percentages of totallymphocytes or as absolute counts(cells/μL) in whole blood</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">K980858 - BDMultitest IMKKit with BDTrucountTubes</td><td colspan="1" rowspan="1">SampleType</td><td colspan="1" rowspan="1">Erythrocyte-lysed whole blood,collected in K3 EDTA bloodcollection tubes</td><td colspan="1" rowspan="1">Same</td></tr></table>

# K. Standard/Guidance Document Referenced (if applicable):

<table><tr><td colspan="1" rowspan="1">STANDARDS</td></tr><tr><td colspan="1" rowspan="1">Title and Reference Number</td></tr><tr><td colspan="1" rowspan="1">Method Comparison and Bias Estimation Using Patient Samples; Approved Guideline (EP09-A2)</td></tr><tr><td colspan="1" rowspan="1">Evaluation of Precision Performance of Clinical Chemistry Devices; Approved Guideline (EP5-A)</td></tr><tr><td colspan="1" rowspan="1">How to Define and Determine Reference Intervals in the Clinical Laboratory; Approved Guideline -Second Edition (C28-A2)</td></tr><tr><td colspan="4" rowspan="1">GUIDANCE</td></tr><tr><td colspan="1" rowspan="1">Document Title</td><td colspan="1" rowspan="1">Office</td><td colspan="1" rowspan="1">Office Division</td><td colspan="1" rowspan="1">Web Page</td></tr><tr><td colspan="1" rowspan="2">Class II Special ControlsGuidance Document:Premarket Notifications forAutomated Differential CellCounters for Immature orAbnormal Blood Cells; FinalGuidance for Industry andFDA</td><td colspan="1" rowspan="2">OIVD</td><td colspan="1" rowspan="2">DIHD</td><td colspan="1" rowspan="1">http://www.fda.gov/cdrh/ode/guidance/1184.html</td></tr><tr><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="2">Guidance for the Content ofPremarket Submissions forSoftware Contained in MedicalDevices - Guidance forIndustry and FDA Staff</td><td colspan="1" rowspan="2">ODE</td><td colspan="1" rowspan="2"></td><td colspan="1" rowspan="1">http://www.fda.gov/cdrh/ode/guidance/337.html</td></tr><tr><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="2">Guidance for Industry andFDA Staff; ReplacementReagent and InstrumentFamily Policy</td><td colspan="1" rowspan="2">OIVD</td><td colspan="1" rowspan="2">−</td><td colspan="1" rowspan="1">http://www.fda.gov/cdrh/oivd/guidance/950.html</td></tr><tr><td colspan="1" rowspan="1"></td></tr></table>

# L. Test Principle:

The BD FACSCanto system for six-color immunophenotyping consists of a BD FACSCanto flow cytometer, BD Multitest 6-color TBNK reagent, BD Trucount tubes, a Windows-based PC workstation, BD FACSCanto clinical software version 2.0 for automated acquisition and analysis.

Determining lymphocyte subset percentages and absolute counts requires: (1) obtaining a whole blood sample; (2) cell-surface antigen staining with the six-color monoclonal antibody reagent in a BD Trucount tube; (3) erythrocyte lysis; and (4) flow cytometric acquisition and analysis of list mode data.

When whole blood is added to the reagent, the fluorochrome-labeled antibodies in the reagent bind specifically to leukocyte surface antigens. During acquisition, the cells travel past the laser beam and scatter the laser light. The stained cells fluoresce. These scatter and fluorescence signals, detected by the instrument, provide information about the cell’s size, internal complexity, and relative fluorescence intensity. BD Multitest reagents employ fluorescence triggering, allowing direct fluorescence gating of the lymphocyte population to reduce contamination of unlysed or nucleated red blood cells in the gate. A precise volume of sample is stained directly in a BD Trucount tube. The lyophilized pellet in the tube dissolves, releasing a known number of fluorescent beads. During analysis, the absolute number $( \mathrm { c e l l s } / \mu \mathrm { L } )$ of positive cells in the sample can be determined by comparing cellular events to bead events. BD FACSCanto clinical software (version 2.0 or higher) determines absolute counts.

# M. Performance Characteristics (if/when applicable):

1. Analytical performance:

a. Precision/Reproducibility:

Precision was determined by running duplicate measurements of commercially available control at different levels o analyte concentration twice a day for a period of 21 operating days on three different instruments.

Standard deviations with $9 5 \%$ confidence limits were calculated for the within-run precision and the total precision of the lymphocyte subset percentages.

Percent CVs with $9 5 \%$ confidence limits were calculated for the within-run precision and the total precision of the lymphocyte subset percentage.

Repeatability of Lymphocyte Subset Percentages   

<table><tr><td rowspan=1 colspan=1>Lymphocyte Subset</td><td rowspan=1 colspan=1>N</td><td rowspan=1 colspan=1>Low SampleSD</td><td rowspan=1 colspan=1>Normal SampleSD</td></tr><tr><td rowspan=1 colspan=1>CD4</td><td rowspan=1 colspan=1>42</td><td rowspan=1 colspan=1>0.64</td><td rowspan=1 colspan=1>0.95</td></tr><tr><td rowspan=1 colspan=1>CD8</td><td rowspan=1 colspan=1>42</td><td rowspan=1 colspan=1>1.07</td><td rowspan=1 colspan=1>0.65</td></tr><tr><td rowspan=1 colspan=1>CD3</td><td rowspan=1 colspan=1>42</td><td rowspan=1 colspan=1>1.17</td><td rowspan=1 colspan=1>0.86</td></tr><tr><td rowspan=1 colspan=1>CD19</td><td rowspan=1 colspan=1>42</td><td rowspan=1 colspan=1>0.89</td><td rowspan=1 colspan=1>062</td></tr><tr><td rowspan=1 colspan=1>CD16+CD56</td><td rowspan=1 colspan=1>42</td><td rowspan=1 colspan=1>0.90</td><td rowspan=1 colspan=1>0.61</td></tr></table>

Within-Device Precision for Lymphocyte Subset Percentages   

<table><tr><td rowspan=1 colspan=1>Lymphocyte Subset</td><td rowspan=1 colspan=1>n</td><td rowspan=1 colspan=1>Low SampleSD</td><td rowspan=1 colspan=1>Normal Sample SD</td></tr><tr><td rowspan=1 colspan=1>CD4</td><td rowspan=1 colspan=1>42</td><td rowspan=1 colspan=1>0.69</td><td rowspan=1 colspan=1>1.23</td></tr><tr><td rowspan=1 colspan=1>CD8</td><td rowspan=1 colspan=1>42</td><td rowspan=1 colspan=1>1.29</td><td rowspan=1 colspan=1>0.81</td></tr><tr><td rowspan=1 colspan=1>CD3</td><td rowspan=1 colspan=1>42</td><td rowspan=1 colspan=1>1.23</td><td rowspan=1 colspan=1>0.90</td></tr><tr><td rowspan=1 colspan=1>CD19</td><td rowspan=1 colspan=1>42</td><td rowspan=1 colspan=1>0.89</td><td rowspan=1 colspan=1>0.62</td></tr><tr><td rowspan=1 colspan=1>CD16+CD56</td><td rowspan=1 colspan=1>42</td><td rowspan=1 colspan=1>0.96</td><td rowspan=1 colspan=1>0.62</td></tr></table>

Repeatability of Lymphocyte Subset Absolute Counts   

<table><tr><td rowspan=1 colspan=1>Lymphocyte Subset</td><td rowspan=1 colspan=1>n</td><td rowspan=1 colspan=1>Low Sample %CV</td><td rowspan=1 colspan=1>Normal Sample%CV</td></tr><tr><td rowspan=1 colspan=1>CD4</td><td rowspan=1 colspan=1>42</td><td rowspan=1 colspan=1>7.6</td><td rowspan=1 colspan=1>4.7</td></tr><tr><td rowspan=1 colspan=1>CD8</td><td rowspan=1 colspan=1>42</td><td rowspan=1 colspan=1>4.1</td><td rowspan=1 colspan=1>4.7</td></tr><tr><td rowspan=1 colspan=1>CD3</td><td rowspan=1 colspan=1>42</td><td rowspan=1 colspan=1>4.0</td><td rowspan=1 colspan=1>4.2</td></tr><tr><td rowspan=1 colspan=1>CD19</td><td rowspan=1 colspan=1>42</td><td rowspan=1 colspan=1>5.7</td><td rowspan=1 colspan=1>5.3</td></tr><tr><td rowspan=1 colspan=1>CD16+CD56</td><td rowspan=1 colspan=1>42</td><td rowspan=1 colspan=1>7.0</td><td rowspan=1 colspan=1>7.9</td></tr></table>

Within-Device Precision of Lymphocyte Subset Absolute Counts   

<table><tr><td rowspan=1 colspan=1>Lymphocyte Subset</td><td rowspan=1 colspan=1>n</td><td rowspan=1 colspan=1>Low Sample %CV</td><td rowspan=1 colspan=1>Normal Sample%CV</td></tr><tr><td rowspan=1 colspan=1>CD4</td><td rowspan=1 colspan=1>42</td><td rowspan=1 colspan=1>8.0</td><td rowspan=1 colspan=1>4.8</td></tr><tr><td rowspan=1 colspan=1>CD8</td><td rowspan=1 colspan=1>42</td><td rowspan=1 colspan=1>5.0</td><td rowspan=1 colspan=1>5.4</td></tr><tr><td rowspan=1 colspan=1>CD3</td><td rowspan=1 colspan=1>42</td><td rowspan=1 colspan=1>4.4</td><td rowspan=1 colspan=1>4.2</td></tr><tr><td rowspan=1 colspan=1>CD19</td><td rowspan=1 colspan=1>42</td><td rowspan=1 colspan=1>6.0</td><td rowspan=1 colspan=1>5.7</td></tr><tr><td rowspan=1 colspan=1>CD16+CD56</td><td rowspan=1 colspan=1>42</td><td rowspan=1 colspan=1>8.0</td><td rowspan=1 colspan=1>7.9</td></tr></table>

# b. Linearity/assay reportable range:

Three whole blood samples were diluted with autologous plasma to known dilutions. High and low pools were created to span the expected $\mathrm { C D 4 + }$ range of 200 to $3 , 0 0 0 { \mathrm { c e l l s } } / { \mu \mathrm { L } }$ . Three replicates at each level were stained and acquired for each specimen. All samples from each specimen were acquired on the same day. Two BD FACSCanto instruments were used in this study. See linear ranges below:

<table><tr><td rowspan=1 colspan=1>Lymphocyte Subset Linear Range (cells/μL)</td><td rowspan=1 colspan=1>Lymphocyte Subset Linear Range (cells/μL)</td><td rowspan=1 colspan=1>$R{2}$</td></tr><tr><td rowspan=1 colspan=1>CD4</td><td rowspan=1 colspan=1>4 - 2,234</td><td rowspan=1 colspan=1>0.998</td></tr><tr><td rowspan=1 colspan=1>CD8</td><td rowspan=1 colspan=1>158 - 1,125</td><td rowspan=1 colspan=1>0.991</td></tr><tr><td rowspan=1 colspan=1>CD3</td><td rowspan=1 colspan=1>498  3,356</td><td rowspan=1 colspan=1>0.996</td></tr><tr><td rowspan=1 colspan=1>CD19</td><td rowspan=1 colspan=1>71-447</td><td rowspan=1 colspan=1>0.989</td></tr><tr><td rowspan=1 colspan=1>CD16+CD56</td><td rowspan=1 colspan=1>0 - 1,559</td><td rowspan=1 colspan=1>0.999</td></tr></table>

c. Traceability, Stability, Expected values (controls, calibrators, or methods): Not applicable.

d. Detection limit: Analytical limits at low levels were validated by accuracy, precision, and linearity studies.   
e. Analytical specificity: Not applicable.   
f. Assay cut-off: Not applicable.

2. Comparison studies:

# a. Method comparison with predicate device:

Whole blood samples (117) were collected and analyzed at two clinical evaluation sites. Lymphocyte subset percentage and absolute counts were enumerated with BD Multitest 6-color TBNK reagent in BD Trucount tubes and analyzed on the BD FACSCanto flow cytometer using BD FACSCanto clinical software. The results were compared with results from the BD Multitest™ IMK kit with BD Trucount tubes, and also were analyzed on the BD FACSCanto flow cytometer using BD FACSCanto clinical software. The results are as follows:

<table><tr><td rowspan=1 colspan=1>LymphocyteSubset</td><td rowspan=1 colspan=1>n</td><td rowspan=1 colspan=1>Unit</td><td rowspan=1 colspan=1>R2</td><td rowspan=1 colspan=1>Slope</td><td rowspan=1 colspan=1>Intercept</td><td rowspan=1 colspan=1>Range</td></tr><tr><td rowspan=2 colspan=1>CD3+ CD4+</td><td rowspan=2 colspan=1>117</td><td rowspan=1 colspan=1>cells/μL</td><td rowspan=1 colspan=1>.995</td><td rowspan=1 colspan=1>0.965</td><td rowspan=1 colspan=1>6.0</td><td rowspan=1 colspan=1>41,593</td></tr><tr><td rowspan=1 colspan=1>%</td><td rowspan=1 colspan=1>.998</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>0.0423</td><td rowspan=1 colspan=1>1-67</td></tr><tr><td rowspan=2 colspan=1>CD3+CD8+</td><td rowspan=2 colspan=1>117</td><td rowspan=1 colspan=1>cells/μL</td><td rowspan=1 colspan=1>.994</td><td rowspan=1 colspan=1>0.956</td><td rowspan=1 colspan=1>7.01</td><td rowspan=1 colspan=1>512,146</td></tr><tr><td rowspan=1 colspan=1>%</td><td rowspan=1 colspan=1>.996</td><td rowspan=1 colspan=1>0.983</td><td rowspan=1 colspan=1>0.00592</td><td rowspan=1 colspan=1>1183</td></tr><tr><td rowspan=2 colspan=1>Total CD3+</td><td rowspan=2 colspan=1>117</td><td rowspan=1 colspan=1>cells/μL</td><td rowspan=1 colspan=1>.995</td><td rowspan=1 colspan=1>0.968</td><td rowspan=1 colspan=1>13.5</td><td rowspan=1 colspan=1>1073,403</td></tr><tr><td rowspan=1 colspan=1>%</td><td rowspan=1 colspan=1>.996</td><td rowspan=1 colspan=1>0.985</td><td rowspan=1 colspan=1>0.895</td><td rowspan=1 colspan=1>3488</td></tr><tr><td rowspan=2 colspan=1>CD3CD19</td><td rowspan=2 colspan=1>117</td><td rowspan=1 colspan=1>cells/μL</td><td rowspan=1 colspan=1>.992</td><td rowspan=1 colspan=1>0.973</td><td rowspan=1 colspan=1>6.97</td><td rowspan=1 colspan=1>11,207</td></tr><tr><td rowspan=1 colspan=1>%</td><td rowspan=1 colspan=1>.993</td><td rowspan=1 colspan=1>0.999</td><td rowspan=1 colspan=1>0.33</td><td rowspan=1 colspan=1>0-36</td></tr><tr><td rowspan=2 colspan=1>CD3-(CD16+CD56)+</td><td rowspan=2 colspan=1>117</td><td rowspan=1 colspan=1>cells/μL</td><td rowspan=1 colspan=1>.99</td><td rowspan=1 colspan=1>0.98</td><td rowspan=1 colspan=1>-0.291</td><td rowspan=1 colspan=1>7918</td></tr><tr><td rowspan=1 colspan=1>%</td><td rowspan=1 colspan=1>.992</td><td rowspan=1 colspan=1>0.985</td><td rowspan=1 colspan=1>0.0603</td><td rowspan=1 colspan=1>251</td></tr></table>

b. Matrix comparison: Not applicable.

3. Clinical studies:

a. Clinical Sensitivity: Not applicable.   
b. Clinical specificity: Not applicable.   
c. Other clinical supportive data (when a. and b. are not applicable): Not applicable.

4. Clinical cut-off: Not applicable.

5. Expected values/Reference range:

A total of 123 donor samples were collected and evaluated. Samples with an even gender distribution and representative of a healthy adult population – between the ages of 18 and 65 years – were tested and used to establish the lymphocyte subset reference intervals. Each sample was stained in duplicate, and the averaged values of the duplicates were used in determining the reference interval.

Reference Intervals for Lymphocyte Subset Percentages   

<table><tr><td rowspan=1 colspan=1>Lymphocyte Subset</td><td rowspan=1 colspan=1>=</td><td rowspan=1 colspan=1>Mean(%)</td><td rowspan=1 colspan=1>95% ReferenceInterval (%)</td></tr><tr><td rowspan=1 colspan=1>CD4</td><td rowspan=1 colspan=1>123</td><td rowspan=1 colspan=1>46.4</td><td rowspan=1 colspan=1>28.2  62.8</td></tr><tr><td rowspan=1 colspan=1>CD8</td><td rowspan=1 colspan=1>123</td><td rowspan=1 colspan=1>24.0</td><td rowspan=1 colspan=1>10.2  40.1</td></tr><tr><td rowspan=1 colspan=1>CD3</td><td rowspan=1 colspan=1>123</td><td rowspan=1 colspan=1>71.1</td><td rowspan=1 colspan=1>49.1  83.6</td></tr><tr><td rowspan=1 colspan=1>CD19</td><td rowspan=1 colspan=1>123</td><td rowspan=1 colspan=1>14.9</td><td rowspan=1 colspan=1>6.5 - 27.0</td></tr><tr><td rowspan=1 colspan=1>CD16+CD56</td><td rowspan=1 colspan=1>123</td><td rowspan=1 colspan=1>11.7</td><td rowspan=1 colspan=1>4.2  25.2</td></tr></table>

# Reference Intervals for Subset Absolute Counts

<table><tr><td rowspan=1 colspan=1>LymphocyteSubset</td><td rowspan=1 colspan=1>n</td><td rowspan=1 colspan=1>Mean(cells/μL)</td><td rowspan=1 colspan=1>95% ReferenceInterval (cells/μL)</td></tr><tr><td rowspan=1 colspan=1>CD4</td><td rowspan=1 colspan=1>123</td><td rowspan=1 colspan=1>1106</td><td rowspan=1 colspan=1>441 -2156</td></tr><tr><td rowspan=1 colspan=1>CD8</td><td rowspan=1 colspan=1>123</td><td rowspan=1 colspan=1>583</td><td rowspan=1 colspan=1>125  1312</td></tr><tr><td rowspan=1 colspan=1>CD3</td><td rowspan=1 colspan=1>123</td><td rowspan=1 colspan=1>1705</td><td rowspan=1 colspan=1>603  2990</td></tr><tr><td rowspan=1 colspan=1>CD19</td><td rowspan=1 colspan=1>123</td><td rowspan=1 colspan=1>354</td><td rowspan=1 colspan=1>107 - 698</td></tr><tr><td rowspan=1 colspan=1>CD16+CD56</td><td rowspan=1 colspan=1>123</td><td rowspan=1 colspan=1>266</td><td rowspan=1 colspan=1>95 - 640</td></tr></table>

# N. Proposed Labeling:

The labeling is sufficient and it satisfies the requirements of 21 CFR Part 809.10.

# O. Conclusion:

The submitted information in this premarket notification is complete and supports a substantial equivalence decision.